Issue 123

Cure Act

The CURE Act in Illinois

Regulatory reform to decriminalise the use of psilocybin is taking place in a dozen states across the US, and is no longer confined to the West Coast – with lawmakers proposing bills in New York, Connecticut and Virginia.

Although many of these do not make allowances for the commercial sale of the psychedelic medicine, progressive frameworks, such as the programme regulating psilocybin services in Oregon, are also being proposed.

Colorado became the second state to vote in favour of the provision of psilocybin, with over one million voting in favour of the Natural Medicine Health Act, and residents of Illinois could soon vote on a similar measure.

READ MORE

SUPPORTING PSYCHEDELIC MEDICINE IN EUROPE

Psychedelic Health spoke with Ken Belotsky and Hayim Raclaw from Negev Capital.

Read More

OREGON ISSUES FIRST PSILOCYBIN LICENCE

The Oregon Health Authority announced it had issued a manufacturer licence to Satori Farms.

Read More

BUSINESS AND INVESTMENT

atai releases 2022 financial results. The company reported a loss of US$152m, with the share price down 65%.

Field Trip obtains CCAA protection.  Following the resignation of CEO Ronan Levy, the company and its subsidiaries seek to protect their financial assets.

Psyence announces private placement. Cantheon Capital has pledged US$1.4m to fund its Phase IIb trial in Australia.

Partnership to combine VR and psychedelic-assisted therapy. Enosis Therapeutics will work with OVID Clinics and the MIND Foundation.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Early Bird tickets on sale for £299 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

Mind Medicine Australia funds psilocybin and MDMA studies. The trials will explore psychedelic-assisted group therapy and treating obsessive compulsive disorder.

Psychedelic therapy for intergenerational trauma. Canadian researchers are studying the use of psilocybin-assisted therapy in First Nation communities.

REGULATION AND LEGISLATION

US congressional panel approves bill to streamline psychedelic research. It aims to expedite studies into Schedule I drugs.

Bill legalising psilocybin proposed in Nevada. The bill would also promote studies into other psychedelic medicines.

Natural Medicine Advisory Board approved by Colorado Senate. The panel will develop rules for psilocybin services.

How the US is embracing psychedelic medicine. An overview of the movement to reschedule psychoactive compounds.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

Mental illness may speed up the aging process. Psychiatric patients carry markers indicating their biological age is older than their chronological age.

London Fire Brigade sees rise in mental health sick days. Days off due to stress, anxiety and depression rose by more than 20% in the last year.

Partner with us